Haug Partners Secures Dismissal of U.S. Fraudulent Transfer Claims for U.K. Internet Marketing Agency READ MORE
Is Silence Disclosure? The Federal Circuit Clarifies its Position on Negative Claim Limitations READ MORE
AstraZeneca AB v. Mylan Pharms. Inc.: Claim Construction of a Percentage Term Guided by the Written Description and Prosecution History READ MORE
No Clear Error to Find Lack of Written Description for a Method of Treatment Patent Despite Separate Disclosures of the Drug, Disease, and Dose (as Part of a Range) READ MORE
